Company intelligence / Profile preview
Dongguan HEC Biopharmaceutical
Dongguan, Guangdong, Chinawork.dyg.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dongguan HEC Biopharmaceutical has a robust pipeline with at least one fusion protein drug candidate, HEC‑88473, targeting FGF21R x GLP‑1R for metabolic and liver-related diseases. This asset is licensed internationally to Apollo Therapeutics as APL‑18881 and supported by an open US IND. The company also has a broader portfolio including small molecule drugs for oncology and viral infections, with several assets having entered Phase II/III trials in China.
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small moleculesFusion proteins/biologics (e.g., FGF21R x GLP‑1R fusion protein)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Apollo Therapeutics (licensee for APL–18881 / HEC–88473)Alphamab Oncology (collaboration on combination therapies in oncology)
Beyond the preview
Go deeper on Dongguan HEC Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dongguan HEC Biopharmaceutical.